MiR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Corcoran, Claire ^a   Rani, Sweta ^a   Breslin, Susan ^a   Gogarty, Martina ^a   Ghobrial, Irene M ^b   Crown, John ^c   O'Driscoll, Lorraine ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b HARVARD MEDICAL SCHOOL   (United States)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Biomarker; Breast cancer; Cancer cell aggression; Drug resistance; IGF1R; MicroRNA 630

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; MESSENGER RNA; MICRORNA; MICRORNA 630; NERATINIB; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; MIRN630 MICRORNA, HUMAN; N-(4-(3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO)-3-CYANO-7-ETHOXY-6-QUINOLYL)-4-(DIMETHYLAMINO)-2-BUTENAMIDE; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE;

ANOIKIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL MOTILITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; POLYMERASE CHAIN REACTION; TUMOR INVASION; BIOSYNTHESIS; BREAST TUMOR; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY;

ANOIKIS; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; QUINAZOLINES; QUINOLINES; RECEPTOR, ERBB-2; RECEPTOR, IGF TYPE 1;

EID: 84899132878     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-71     Document Type: Article

References (43)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182. 10.1126/science.3798106, 3798106.
2. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012, 9:16-32.
3. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999, 17:2639-2648.
4. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001, 1:85-94.
5. Wang L, Zhang Q, Zhang J, Sun S, Guo H, Jia Z, Wang B, Shao Z, Wang Z, Hu X. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer 2011, 11:248. 10.1186/1471-2407-11-248, 3141770, 21676217.
6. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, Halsey W, Sathe GM, Martin AM, Gilmer TM. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 2009, 69:6871-6878. 10.1158/0008-5472.CAN-08-4490, 19671800.
7. Browne BC, O'Brien N, Duffy MJ, Crown J, O'Donovan N. HER-2 signaling and inhibition in breast cancer. Curr Cancer Drug Targets 2009, 9:419-438. 10.2174/156800909788166484, 19442060.
8. Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene 2007, 26:3637-3643. 10.1038/sj.onc.1210379, 17530017.
9. Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, Awada A, Ranade A, Jiao S, Schwartz G, Abbas R, Powell C, Turnbull K, Vermette J, Zacharchuk C, Badwe R. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010, 28:1301-1307. 10.1200/JCO.2009.25.8707, 20142587.
10. Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, Munster P, Frakes L, Kelly S, Garcia AA, Cleator S, Uttenreuther-Fischer M, Jones H, Wind S, Vinisko R, Hickish T. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat 2012, 133:1057-1065. 10.1007/s10549-012-2003-y, 3387495, 22418700.
11. Corcoran C, Friel AM, Duffy MJ, Crown J, O'Driscoll L. Intracellular and extracellular microRNAs in breast cancer. Clin Chem 2011, 57:18-32. 10.1373/clinchem.2010.150730, 21059829.
12. Zhang B, Pan X, Cobb G, Anderson T. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007, 302:1-12. 10.1016/j.ydbio.2006.08.028, 16989803.
13. Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A, Servant N, Paccard C, Hupé P, Robert T, Ripoche H, Lazar V, Harel-Bellan A, Dessen P, Barillot E, Kroemer G. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 2010, 70:1793-1803. 10.1158/0008-5472.CAN-09-3112, 20145152.
14. Huang Y, Chuang A, Hao H, Talbot C, Sen T, Trink B, Sidransky D, Ratovitski E. Phospho-ΔNp63α is a key regulator of the cisplatin-induced microRNAome in cancer cells. Cell Death Differ 2011, 18:1220-1230. 10.1038/cdd.2010.188, 3131951, 21274007.
15. Kuo TC, Tan CT, Chang YW, Hong CC, Lee WJ, Chen MW, Jeng YM, Chiou J, Yu P, Chen PS, Wang MY, Hsiao M, Su JL, Kuo ML. Angiopoietin-like protein 1 suppresses SLUG to inhibit cancer cell motility. J Clin Invest 2013, 123:1082-1095. 10.1172/JCI64044, 3582121, 23434592.
16. Farhana L, Dawson MI, Murshed F, Das JK, Rishi AK, Fontana JA. Upregulation of miR-150* and miR-630 induces apoptosis in pancreatic cancer cells by targeting IGF-1R. PLoS One 2013, 8:e61015. 10.1371/journal.pone.0061015, 3651232, 23675407.
17. Rani S, Clynes M, O'Driscoll L. Detection of amplifiable mRNA extracellular to insulin-producing cells: potential for predicting beta cell mass and function. Clin Chem 2007, 53:1936-1944. 10.1373/clinchem.2007.087973, 17717131.
18. Hennessy E, O'Driscoll L. MicroRNA expression analysis: techniques suitable for studies of intercellular and extracellular microRNAs. Methods Mol Biol 2011, 784:99-107. 10.1007/978-1-61779-289-2_7, 21898215.
19. Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, Canu V, Mori F, Antoniani B, Di Benedetto A, Santoro R, Germoni S, De Angelis F, Cambria A, Avraham R, Grasso G, Strano S, Muti P, Mottolese M, Yarden Y, Domany E, Blandino G. miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours. EMBO Mol Med 2012, 4:1214-1229. 10.1002/emmm.201201483, 3494877, 23125021.
20. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006, 66:1630-1639. 10.1158/0008-5472.CAN-05-1182, 16452222.
21. Hegde PS, Rusnak D, Bertiaux M, Alligood K, Strum J, Gagnon R, Gilmer TM. Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. Mol Cancer Ther 2007, 6:1629-1640. 10.1158/1535-7163.MCT-05-0399, 17513611.
22. O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 2010, 9:1489-1502. 10.1158/1535-7163.MCT-09-1171, 20501798.
23. O'Neill F, Madden SF, Aherne ST, Clynes M, Crown J, Doolan P, O'Connor R. Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines. Mol Cancer 2012, 11:41. 10.1186/1476-4598-11-41, 3439312, 22709873.
24. Corcoran C, Rani S, O'Brien K, O'Neill A, Prencipe M, Sheikh R, Webb G, McDermott R, Watson W, Crown J, O'Driscoll L. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS One 2012, 7:e50999. 10.1371/journal.pone.0050999, 3519481, 23251413.
25. O'Driscoll L, Kenny E, Mehta J, Doolan P, Joyce H, Gammell P, Hill A, O'Daly B, O'Gorman D, Clynes M. Feasibility and relevance of global expression profiling of gene transcripts in serum from breast cancer patients using whole genome microarrays and quantitative RT-PCR. Cancer Genomics Proteomics 2008, 5:94-104.
26. Friel A, Corcoran C, Crown J, O'Driscoll L. Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer. Breast Cancer Res Treat 2010, 123:613-625. 10.1007/s10549-010-0980-2, 20549336.
27. Rani S, Gately K, Crown J, O'Byrne K, O'Driscoll L. Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma. Cancer Biol Ther 2013, 14:1104-1112. 10.4161/cbt.26370, 24025412.
28. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 2007, 14:3629-3637. 10.1245/s10434-007-9583-5, 17909916.
29. Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 2007, 37:1979-1987.
30. Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray MJ, Cheng H, Hoff PM, Ellis LM. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 2006, 12:4147-4153. 10.1158/1078-0432.CCR-06-0038, 16857785.
31. Paoli P, Giannoni E, Chiarugi P. Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta 1833, 2013:3481-3498.
32. Gallardo A, Lerma E, Escuin D, Tibau A, Muñoz J, Ojeda B, Barnadas A, Adrover E, Sánchez-Tejada L, Giner D, Ortiz-Martínez F, Peiró G. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer 2012, 106:1367-1373. 10.1038/bjc.2012.85, 3326683, 22454081.
33. Browne BC, Crown J, Venkatesan N, Duffy MJ, Clynes M, Slamon D, O'Donovan N. Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. Ann Oncol 2011, 22:68-73. 10.1093/annonc/mdq349, 20647220.
34. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001, 93:1852-1857. 10.1093/jnci/93.24.1852, 11752009.
35. Luk F, Yu Y, Walsh WR, Yang JL. IGF1R-targeted therapy and its enhancement of doxorubicin chemosensitivity in human osteosarcoma cell lines. Cancer Invest 2011, 29:521-532. 10.3109/07357907.2011.606252, 21843050.
36. Wang YH, Xiong J, Wang SF, Yu Y, Wang B, Chen YX, Shi HF, Qiu Y. Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo. Mol Cell Biochem 2010, 341:225-233. 10.1007/s11010-010-0453-2, 20376536.
37. Dunn SE, Ehrlich M, Sharp NJ, Reiss K, Solomon G, Hawkins R, Baserga R, Barrett JC. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 1998, 58:3353-3361.
38. Long L, Rubin R, Brodt P. Enhanced invasion and liver colonization by lung carcinoma cells overexpressing the type 1 insulin-like growth factor receptor. Exp Cell Res 1998, 238:116-121. 10.1006/excr.1997.3814, 9457063.
39. Xie Y, Skytting B, Nilsson G, Brodin B, Larsson O. Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. Cancer Res 1999, 59:3588-3591.
40. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J, Fan Z. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003, 22:3205-3212. 10.1038/sj.onc.1206394, 12761490.
41. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005, 65:11118-11128. 10.1158/0008-5472.CAN-04-3841, 16322262.
42. Ueda S, Hatsuse K, Tsuda H, Ogata S, Kawarabayashi N, Takigawa T, Einama T, Morita D, Fukatsu K, Sugiura Y, Matsubara O, Mochizuki H. Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer. Mod Pathol 2006, 19:788-796.
43. Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 2007, 13:2795-2803. 10.1158/1078-0432.CCR-06-2077, 17473213.